Thermo Fisher Scientific Acquires Brammer Bio for $1.7 Billion
March 25, 2019
Thermo Fisher Scientific agreed to acquire Brammer Bio, a viral vector CDMO focused on gene and cell therapies, for approximately $1.7 billion in cash. The deal expands Thermo Fisher’s pharma services and viral vector manufacturing capabilities to support high-growth gene and cell therapy markets and brings a team of nearly 600 employees into its pharma services business.
- Buyers
- Thermo Fisher Scientific
- Targets
- Brammer Bio
- Sellers
- Ampersand Capital Partners, Brammer Bio founders
- Industry
- Biotechnology
- Location
- Massachusetts, United States
- Transaction Type
- Buyout
Explore More
Build a buyer list for your deal
Find active buyers from recent acquisition patterns and move straight into outreach.